Company profile

Vifor Pharma

Iron deficiency / nephrology therapeutics (part of CSL group since 2022)

Privately held: no public share price · Switzerland

Assets

(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Difelikefalin(Korsuva)
Approved
Kappa-opioid receptor (agonist, peripherally restricted)Peptide
Chronic Kidney Disease
Ferric carboxymaltose(Injectafer / Ferinject)
Approved
Iron repletionOther
Heart FailureChronic Kidney Disease
Patiromer(Veltassa)
Approved
Gastrointestinal potassium binderSmall molecule
Heart FailureChronic Kidney Disease
Sucroferric oxyhydroxide(Velphoro)
Approved
Phosphate binderSmall molecule
Chronic Kidney Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.